Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jäger,Wilma Barcellini,Catherine Broome,Morie A. Gertz,Anita Hill,Quentin A. Hill,Bernd Jilma,David J. Kuter,Marc Michel,Marco Montillo,Alexander Röth,Sacha Zeerleder,Sigbjørn Berentsen +12 more
Reads0
Chats0
TLDR
The First International Consensus Group recommended that Corticosteroids remain first-line therapy for warm-AIHA, while the addition of rituximab should be considered early in severe cases and if no prompt response to steroids is achieved.About:
This article is published in Blood Reviews.The article was published on 2020-05-01 and is currently open access. It has received 224 citations till now. The article focuses on the topics: Cold agglutinin disease & Autoimmune hemolytic anemia.read more
Citations
More filters
Journal ArticleDOI
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.
TL;DR: The putative mechanisms behind these phenomena will be explained along with other recent achievements in the understanding of pathogenesis in these disorders, and novel targeted treatments, in particular complement-directed therapies, are reviewed.
Journal ArticleDOI
Cold agglutinin disease revisited: a multinational, observational study of 232 patients
Sigbjørn Berentsen,Wilma Barcellini,Shirley D'Sa,Ulla Randen,Tor Henrik Anderson Tvedt,Bruno Fattizzo,Einar Haukås,Megan Kell,Robert Brudevold,Anders E.A. Dahm,Anders E.A. Dahm,Jakob Dalgaard,Hege Frøen,Randi Fykse Hallstensen,Pernille H. Jæger,Henrik Hjorth-Hansen,Agnieszka Malecka,Agnieszka Malecka,Markku Oksman,Jürgen Rolke,Mallika Sekhar,Jon Hjalmar Sørbø,Eirik Brekka Tjønnfjord,Galina Tsykunova,Geir E. Tjønnfjord +24 more
TL;DR: In patients responding to rituximab-bendamustine, median response duration was not reached after 88 months, and estimated 5-year sustained remission was 77%.
Journal ArticleDOI
The Changing Landscape of Autoimmune Hemolytic Anemia
TL;DR: On the whole, the double-edged sword of new pathogenetic insights and therapies has changed the landscape of AIHA, both providing enthusiastic knowledge and complicating the clinical management of this disease.
Journal ArticleDOI
How I treat cold agglutinin disease
TL;DR: In this article, a review of the treatment options for cold agglutinin disease (CAD) is presented, where the authors identify two major steps in CAD pathogenesis, clonal B-cell lymphoproliferation and complement-mediated hemolysis.
Journal ArticleDOI
New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1.
TL;DR: A comprehensive review of the main clinical characteristics, diagnosis, and pathogenic mechanisms of AIHA are provided, along with classic and new therapeutic approaches.
References
More filters
Journal ArticleDOI
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero,Roberto Stasi,Terry Gernsheimer,Marc Michel,Drew Provan,Donald M. Arnold,James B. Bussel,Douglas B. Cines,Beng H. Chong,Nichola Cooper,Bertrand Godeau,Klaus Lechner,Maria Gabriella Mazzucconi,Robert McMillan,Miguel A. Sanz,Paul Imbach,Victor S. Blanchette,Thomas Kühne,Marco Ruggeri,James N. George +19 more
TL;DR: An International Working Group of recognized expert clinicians convened a 2-day structured meeting to define standard terminology and definitions for primary ITP and its different phases and criteria for the grading of severity, and clinically meaningful outcomes and response.
Journal ArticleDOI
FcRn: the neonatal Fc receptor comes of age
TL;DR: The neonatal Fc receptor for IgG (FcRn) has been well characterized in the transfer of passive humoral immunity from a mother to her fetus and throughout life, FcRm protects IgG from degradation, thereby explaining the long half-life of this class of antibody in the serum.
Journal ArticleDOI
Mechanisms of Cell Protection by Heme Oxygenase-1
TL;DR: The mechanism underlying this cytoprotective effect relies on the ability of HO-1 to catabolize free heme and prevent it from sensitizing cells to undergo programmed cell death.
Journal ArticleDOI
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Steven P. Treon,Lian Xu,Guang Yang,Yangsheng Zhou,Xia Liu,Yang Cao,Patricia Sheehy,Robert Manning,Christopher J. Patterson,Christina K. Tripsas,Luca Arcaini,Geraldine S. Pinkus,Scott J. Rodig,Aliyah R. Sohani,Nancy L. Harris,Jason M. Laramie,Donald A Skifter,Stephen E Lincoln,Zachary R. Hunter +18 more
TL;DR: MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating WaldenStröm’s macrogalobulinesia and non-IgM LPL from B-cell disorders that have some of the same features.
Journal ArticleDOI
Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs
La García Rodríguez,Hershel Jick +1 more
TL;DR: NSAIDS should be used cautiously in patients who have other risk factors for UGIB; these include advanced age, smoking, history of peptic ulcer, and use of oral corticosteroids or anticoagulants.
Related Papers (5)
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.
Wilma Barcellini,Bruno Fattizzo,Anna Zaninoni,Tommaso Radice,Ilaria Nichele,Eros Di Bona,Monia Lunghi,C Tassinari,Fiorella Alfinito,Antonella Ferrari,Anna Paola Leporace,Pasquale Niscola,Monica Carpenedo,Carla Boschetti,Nicoletta Revelli,Maria Antonietta Villa,Dario Consonni,Laura Scaramucci,Paolo de Fabritiis,Giuseppe Tagariello,Gianluca Gaidano,Francesco Rodeghiero,Agostino Cortelezzi,Alberto Zanella +23 more
Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial.
Sigbjørn Berentsen,Ulla Randen,Ulla Randen,Markku Oksman,Henrik Birgens,Tor Henrik Anderson Tvedt,Tor Henrik Anderson Tvedt,Jakob Dalgaard,Eivind Galteland,Eivind Galteland,Einar Haukås,Robert Brudevold,Jon Hjalmar Sørbø,Inger Anne Næss,Agnieszka Malecka,Agnieszka Malecka,Geir E. Tjønnfjord,Geir E. Tjønnfjord +17 more